Advertisement
Journal Home
Search for
Advanced Search - MEDLINE - My Recent Searches - My Saved Searches - Search Tips
More periodicals:

103 Periodical Search Results

You searched for "anastrozole" OR "zd1033" OR "zd 1033" OR "icid1033" OR "arimidex" OR "ici d1033" OR "anastrazole" within European Journal of Cancer

New Search | Edit Search | Save Search | Save Search as an E-mail Alert

  Viewing 1-20  of 103 results   Next 20>

Results Page:  [1]  2  3  4  5  6

display abstract citation download email a colleague
Display:

  1. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
    Henning T. Mouridsen, Nicholas J. Robert
    European Journal of Cancer
    August 2005 (Vol. 41, Issue 12, Pages 1678-1689)
    Abstract | Full Text | Full-Text PDF (181 KB)

  1. A phase II study of a potent and selective aromatase inhibitor, anastrozole (ZD-1033), in Japanese postmenopausal women with advanced/recurrent breast cancer
    H. Koyama
    European Journal of Cancer
    September 1998 (Vol. 34Supplement 5, Page S21)
    Full-Text PDF (147 KB)

  1. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
    I. Vergote, J. Bonneterre, B. Thürlimann, J. Robertson, M. Krzakowski, L. Mauriac, L. Koralewski, A. Webster, M. Steinberg, M. von Euler, on behalf of the Arimidex Study Group
    European Journal of Cancer
    September 2000 (Vol. 36Supplement 4, Pages 84-85)
    Abstract | Full Text | Full-Text PDF (68 KB)

  1. Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women
    I Vergote, on behalf of the Faslodex 0020 and 0021 investigators
    European Journal of Cancer
    September 2002 (Vol. 38Supplement 6, Pages 57-58)
    Full Text | Full-Text PDF (68 KB)

  1. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
    J.M Nabholtz, J Bonneterre, A Buzdar, J.F.R Robertson, B Thürlimann, for the Arimidex Writing Committee on behalf of the Investigators
    European Journal of Cancer
    August 2003 (Vol. 39, Issue 12, Pages 1684-1689)
    Abstract | Full Text | Full-Text PDF (180 KB)

  1. Effects of third-generation aromatase inhibitors on bone
    Eugene McCloskey
    European Journal of Cancer
    May 2006 (Vol. 42, Issue 8, Pages 1044-1051)
    Abstract | Full Text | Full-Text PDF (216 KB)

  1. Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
    B. Thürlimann, J.F.R. Robertson, J.M. Nabholtz, A. Buzdar, J. Bonneterre, on behalf of the Arimidex Study Group.
    European Journal of Cancer
    November 2003 (Vol. 39, Issue 16, Pages 2310-2317)
    Abstract | Full Text | Full-Text PDF (247 KB)

  1. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle? , 15 August 2007
    Laura Biganzoli, Sara Licitra, Wederson Claudino, Marta Pestrin, Angelo Di Leo
    European Journal of Cancer
    October 2007 (Vol. 43, Issue 15, Pages 2270-2278)
    Abstract | Full Text | Full-Text PDF (337 KB)

  1. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex)∗ with megestrol acetate in postmenopausal patients with advanced breast cancer
    W. Jonat, A. Howell, C. Blomqvist, W. Eiermann, G. Winblad, C. Tyrrell, L. Mauriac, H. Roche, S. Lundgren, R. Hellmund, M. Azab
    European Journal of Cancer
    March 1996 (Vol. 32, Issue 3, Pages 404-412)
    Abstract | Abstract + References | Full-Text PDF (1099 KB)

  1. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy
    C Harper-Wynne, R.C Coombes
    European Journal of Cancer
    May 1999 (Vol. 35, Issue 5, Pages 744-746)
    Abstract | Full Text | Full-Text PDF (49 KB)

  1. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: Where are we now?
    M. Baum
    European Journal of Cancer
    August 2005 (Vol. 41, Issue 12, Pages 1667-1677)
    Abstract | Full Text | Full-Text PDF (287 KB)

  1. Information provision for patients by breast cancer teams about the side-effects of hormone treatments
    Rhona McGurk, Lesley Fallowfield, Zoë Winters
    European Journal of Cancer
    August 2006 (Vol. 42, Issue 12, Pages 1760-1767)
    Abstract | Full Text | Full-Text PDF (287 KB)

  1. Anti-oestrogenic chemoprevention of breast cancer—the need to progress
    Trevor J. Powles
    European Journal of Cancer
    March 2003 (Vol. 39, Issue 5, Pages 572-579)
    Abstract | Full Text | Full-Text PDF (144 KB)

  1. P100 ‘Arimidex’ (anastrozole): Lack of interactions with tamoxifen, antipyrine, cimetidine and warfarin
    M. Dowsett, R. Yates, Y.W.J. Wong, On behalf of the Arimidex Study Group
    European Journal of Cancer
    February 1998 (Vol. 34Supplement 1, Pages S39-S40)
    Full-Text PDF (306 KB)

  1. PP-8-5 A randomised study assessing oestrogen suppression with arimidex™ (Anastrozole) and formestane in postmenopausal advanced breast cancer (ABC) patients
    M. Dowsett, D.A. Vorobiof, U.R. Kleeberg, R.P. Carrion, D.J. Dodwell, J.F.R. Robertson, L Calvo, Arimidex Study Group
    European Journal of Cancer
    1996 (Vol. 32Supplement 2, Pages 49-50)
    Full-Text PDF (358 KB)

  1. The effect of anastrozole (Arimidex™) on serum lipids — a randomized comparison of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal women with Advanced Breast Cancer
    J. Dewar, J.M. Nabholtz, J. Bonneterre, A. Buzdar, J.F.R. Robertson, B. Thürlimann, G. Clack
    European Journal of Cancer
    September 2001 (Vol. 37Supplement 5, Page 5)
    Full-Text PDF (127 KB)

  1. Endocrine treatment options for advanced breast cancer – the role of fulvestrant
    J.F.R. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, A. Makris, J.W.R. Nortier, K. Possinger, L.-E. Rutqvist
    European Journal of Cancer
    February 2005 (Vol. 41, Issue 3, Pages 346-356)
    Abstract | Full Text | Full-Text PDF (402 KB)

  1. Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
    L. Mauriac, J.E. Pippen, J. Quaresma Albano, S.Z. Gertler, C.K. Osborne
    European Journal of Cancer
    June 2003 (Vol. 39, Issue 9, Pages 1228-1233)
    Abstract | Full Text | Full-Text PDF (196 KB)

  1. Comment on “Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results” by J.-M. Nabholtz et al.
    H.T. Mouridsen, H.A. Chaudri-Ross
    European Journal of Cancer
    May 2004 (Vol. 40, Issue 7, Pages 1095-1096)
    Full Text | Full-Text PDF (100 KB)

  1. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole
    C. Rose, O. Vtoraya, A. Pluzanska, N. Davidson, M. Gershanovich, R. Thomas, S. Johnson, J.J. Caicedo, H. Gervasio, G. Manikhas, F. Ben Ayed, S. Burdette-Radoux, H.A. Chaudri-Ross, R. Lang
    European Journal of Cancer
    November 2003 (Vol. 39, Issue 16, Pages 2318-2327)
    Abstract | Full Text | Full-Text PDF (213 KB)
display abstract citation download email a colleague
Display:

  Viewing 1-20  of 103 results   Next 20>

Results Page:  [1]  2  3  4  5  6

New Search | Edit Search | Save Search | Save Search as an E-mail Alert

Advertisement

Copyright © 2009 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us |
The content on this site is intended for health professionals.